Founded in 2012, iGenomX initially sought to provide clinical sequencing for recessive genetic disorders. However, available commercial technology failed to produce a comprehensive test, missing nearly 30 percent of known causal mutations. Compelled to develop a technology that is capable of detecting all genetic variation, iGenomX pivoted to begin work on a low-cost sample preparation technology. Invented in the laboratory of Dr. Daniel Salomon at The Scripps Research Institute (La Jolla, CA) and licensed exclusively to iGenomX, this technology has become the core of all iGenomX NGS applications. In 2014, iGenomX began operations in Southern California to further develop the technology and intellectual property. IGenomX currently has five product lines in development.
Founder/CEO | Keith Brown
Mr. Brown has been with the company since operations began in January of 2014. A co-founder of the company, Mr. Brown currently holds the position of Chief Executive Officer. Previously, Mr. Brown served as Vice President of Sales for Complete Genomics Inc., a DNA sequencing company located in Silicon Valley. Complete genomics is the first company to offer whole human genome sequencing services on a proprietary sequencing platform. After the acquisition of Complete Genomics by BGI, Mr. Brown became CEO of the BGI Americas Corporation. Prior to joining Complete in 2011, Mr. Brown was the National Sales Director at RainDance Technologies, a small start-up founded by serial entrepreneur Jonathan Rothberg. At RainDance, Mr. Brown led the commercialization strategy for a novel micro-droplet PCR system, with applications in the burgeoning Next-Generation Sequencing Industry. Mr. Brown held that position at RainDance from 2007 through his departure in 2011 to join Complete Genomics. Prior to RainDance, Mr. Brown held sales and market development positions at Affymetrix, Inc., the leading supplier of DNA microarrays. Mr. Brown has held numerous positions at Li-Cor Biosciences, a manufacturer of automated DNA sequencing instrumentation, and at Chemicon International (acquired by Serologicals). Mr. Brown started his career as a molecular biologist at Chemicon International supporting the launch of PCR based assays for infectious disease and genetic disorders. Mr. Brown has one issued and five patents pending in the field of nucleic acid analysis.
Chief Scientist | Daniel Salomon, M.D.
Dr. Salomon will be fondly remembered for his wisdom and brilliance, which continue to guide our greater understanding of life.
Doctor Salomon was a Professor at The Scripps Research Institute, Department of Molecular and Experimental Medicine and Program Medical Director, Scripps Center for Organ Transplantation. He was the past-President of the American Society of Transplantation. Dr. Salomon has published 124 peer-reviewed manuscripts, 43 chapters and numerous reviews and has edited 3 books. He has served on numerous national and international committees, including Executive Board member, Program Committee Chair, Cell Transplantation Committee Chair and Xenotransplantation Committee Chair for American Society of Transplantation; Chair, National Institutes of Health Islet Cell Resources Steering Committee; Chair, NIH Genomics of Transplantation Cooperative Research Program Steering Committee; Founding Member, US Secretary of Health’s Xenotransplantation Advisory Committee; and Chair, FDA Biological Response Modifiers Advisory Committee. He has served on multiple NIH Study Sections and Special Emphasis Panels and is presently a standing member of AITC. Dr. Salomon’s laboratory work was focused on various aspects of organ and cell transplantation and immunology with a primary focus on functional genomics, proteomics and genetics. His research objectives included discovering biomarkers for the diagnosis of acute and chronic rejection that will enable personalized management of immunosuppression; discovering prognostic markers for transplant outcomes using genetics, transcriptional profiling and proteomics; and understanding the multi-dimensionality of transcriptional regulation. These studies include microRNA regulation, alternative splicing and RNA binding proteins and the dynamic impact of epigenetic changes, both methylation and histone marking, on lymphocyte activation and differentiation into memory. He received his BS from Northwestern University and MD from Stritch-Loyola School of Medicine in Chicago. Dr. Salomon trained at Cedars-Sinai/UCLA for internal medicine and did his postdoctoral work in transplantation and immunology at Harvard Medical School. Dr. Salomon was a Founder and Director of Transplant Genomics Inc.
Senior Scientist-Assay Development | Steve Head, M.S.
Steven Head advises iGenomX on technology development and laboratory operations. Mr. Head has been the Director of the Scripps Research Institute Microarray Core since its inception in 1998. He also is the co-director of the Next Generation Sequencing Core Facility at TSRI, a facility he established in 2008. Mr. Head has participated in multiple NIH-funded projects at TSRI, has coauthored more than 40 peer-reviewed publications and is co-inventor on 5 sequencing/microarray-related patents. Prior to joining TSRI, he was a Staff Scientist at Molecular Tool Inc. in Baltimore, MD, where he developed microarray-based genotyping technologies. Mr. Head received his BS and MS degrees in Biology from the University of California at San Diego.
Senior Scientist, Biochemistry | Phillip Ordukhanian, Ph.D.
Phillip Ordoukhanian advises iGenomX on biochemistry and laboratory operations. Dr. Ordoukhanian has been the Director of the Scripps Research Institute’s Protein and Nucleic Acid Core facility since 2001. He is also the co-director of the Next Generation Sequencing Core Facility at TSRI, a facility he established in 2008. Dr. Ordoukhanian has participated in multiple NIH-funded projects at TSRI, has coauthored more than 25 peer-reviewed publications and is co-inventor on one sequencing-related and one biochemical-related patent. Dr. Ordoukhanian received his B.S. in chemistry from the University of Missouri-St. Louis. He received his Ph.D. from Washington University in St. Louis under the direction of John-Stephen Taylor, synthesizing photochemical DNA damage products and studying their mutational spectrum using in vitro and in vivo systems. He subsequently joined the Scripps Research Institute in 1997 as a post-doctoral candidate in the laboratory of Gerald F. Joyce, where he studied the selection and molecular evolution RNA and DNA enzymes.
Senior Scientist, Research and Development | Azeem Siddique, Ph.D.
Dr. Siddique started at iGenomX in 2014 as a Research Technician. He currently leads the Research and Development team and is co-author of two iGenomX patents. Prior to iGenomX, Dr Siddique was a staff scientist at the university of California San Diego and a lecturer on Molecular biology of photosynthetic organisms. Postdoctoral work at Oxford University focused on transposable elements in human genomes. Dr. Siddique received his PhD in microbiology from Columbia University in New York City.
Bioinformatics | Nils Homer, Fulcrum Genomics
Nils Homer is a Founding Partner at Fulcrum Genomics LLC and has over a decade of cutting-edge experience developing methods and software for the analysis of next-generation sequencing data. He has led high-pace technology and product development efforts at both industry and academic positions, and has directed teams of software developers to support the largest academic genome sequencing facility in the world for both research and clinical applications. Nils has also participated in the technology development and subsequent commercial launch of multiple sequencing assays and technologies, providing critical understanding for technical improvements in chemistry, molecular biology, and software. He combines his skill in developing novel methods, algorithms, and software with his understanding of the data produced to provide key insights into biological research and discovery. Nils holds a Masters and PhD in Computer Science from UCLA investigating methods applied to genomics, including alignment and variant detection for whole genome sequencing. He received his BA (Computer Science and Mathematics) from Colgate University. Nils currently serves on the Scientific Advisory Board for Edico Genome.
Board of Directors
Founder and CEO of iGenomX
Kirk D. Malloy, Ph.D.
Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for over 20 years. He founded BioAdvisors in April 2016 which provides strategic consulting services to life science, diagnostics and genomics companies. He also currently serves as Lead Independent Director for Organovo (ONVO); corporate director for Nanostring Technologies (NSTG); Executive Chairman for Agilome; and as a member of the board of directors for Edico Genome, iGenomX and JumpCode Genomics.
For the previous 13 years, he was Senior Vice President and General Manager of Life Sciences and Applied Markets at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays and software for the life science and diagnostics markets. In this role he ran the company’s largest business unit with a P&L of over $1B and was responsible for the company's core platform technologies. His business unit served the life sciences and applied markets (Agrigenomics, Micriobiology, Transplant Biology, Forensics, Complex Diseases and Healthy Clinical Genomes). He joined Illumina in 2002 and previously managed a team of 450 in 50 countries as Vice President of Global Customer Solutions and Vice President of Quality, building and leading the commercial support and training organization and a professional service business generating more than $150M in annual revenues.
Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University. He completed a certification for Corporate Directors at UCLA’s Anderson School in 2012. He also serves on the Board of Trustees for the Pacific Ridge School, and is on the Dean’s Advisory Board for the University of Delaware. He has 12 peer-reviewed publications and book chapters, dozens of invited and contributed scientific presentations and has been a reviewer for various scientific journals.
Mr. Chen is a Managing Director at CWC Healthtech Partners, a leading investor in iGenomX. Eugene partnered with CWC HealthTech Advisors in January 2013 following two decades as an entrepreneur and venture capitalist focused on healthcare. Eugene is a founding principal of Medenovo, LLC, an investment firm focused on medical devices. He is co-founder and CEO of SPIWay, LLC, a neuro-endoscopy company, and co-founder and CEO of FRESCA Medical, a company developing a consumer friendly device for the treatment of sleep apnea. Previously, Eugene was founder/CEO of USGI Medical, a minimally-invasive-obesity-surgery company; a Venture Partner and entrepreneur-in-residence with Alta Partners, a venture capital firm located in California's Silicon Valley; General Manager/Sr. VP at Applied Medical Resources Corporation; and Founder/CEO of BioFlex/Kinesys Inc., a knee orthotics company. Eugene also serves as manager of TEKE, LLC, a medical device incubator; a board member of Microfabrica Inc.; and a member of the board of trustees of the Pacific Ridge School. Eugene holds an M.B.A. from the Anderson School at UCLA and a B.S. in Mechanical Engineering from Cornell University. He and his wife, Katie, live in Carlsbad with their two sons, with whom Eugene enjoys spending quality family time "fighting" at the local Tae Kwan Do studio.
Before joining the board of iGenomX, Joel spent four years as an investment professional at Baird Venture Partners where he focused on venture and growth equity investments in life sciences tools & diagnostics, medical devices and healthcare services. During his time at Baird, Joel was involved in the investment in, and was an invitee of the Board of Accuri Cytometers (acquired by Becton Dickenson). He also was actively involved with the firm’s investments in Incept (acquired by Hologic) and Palyon Medical, as well as the fund’s successful raising of its third fund. Prior to Baird Venture Partners, Joel was an investment banking analyst in Piper Jaffray’s healthcare group where he was a member of deal teams that completed buy-side & sell-side transactions, primary offerings, secondary offerings and private raises. Before Piper Jaffray, Joel was an analyst in the Business Planning Group at Boston Scientific Corporation (BSX) where he evaluated internal research and development projects and acquisition integration. Joel also previously worked as a summer associate at Norwest Equity Partners (NEP) where he was involved in NEP’s investment in the Momentum group and worked with Surgical Investment Systems, a portfolio company of NEP. Joel holds a BS with honors and distinction in Biomedical Engineering from the University of Wisconsin, a Master of Engineering Management from Duke University and an MBA from Northwestern University’s Kellogg Graduate School of Business.